# Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability

Canonical: https://abierto.us/opportunities/rrpvrpp2408mrnalongterm

- Solicitation number: RRPV-RPP-24-08-mRNALongTerm
- Notice type: Special notice
- Status: Closed. Deadline was December 16, 2024 at 1:00 PM EST
- Department: Department of Health and Human Services
- Agency: Office of Assistant Secretary for Preparedness and Response
- Contracting office: Barda - Aspr / Daappo / Barda DCMA (75A501)
- NAICS: 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Product or service code: AN42 Health R&D Services; Health Care - Other; Applied Research
- Place of performance: Washington, District of Columbia
- County: District of Columbia (FIPS 11001). https://abierto.us/counties/district-of-columbia-dc-11001
- City: Washington. https://abierto.us/cities/washington-dc-1150000
- First posted: September 3, 2024
- Last posted: September 3, 2024
- SAM.gov: https://sam.gov/workspace/contract/opp/e6e00ff3a2ee4b69af18ae7b8d5d6f1c/view

## Description

This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority (BARDA) entitiled "Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability". The full RPP and information on joining the consortium can be accessed through the RRPV website www.rrpv.org.

BARDA seeks to establish a long-term partnership centered around the development of a broad preparedness and response capability that can be rapidly and flexibly leveraged toward vaccine development for pandemic influenza or other priority pathogen threats. BARDA envisions an initial focus on influenza mRNA vaccine development that complements existing pandemic influenza response capabilities.

As the program matures beyond licensure of influenza vaccines, there will be increased focus on continually ‘exercising’ preparedness and response efforts at small scale to ensure readiness to rapidly pivot to address pandemic influenza or any other emerging infectious disease that poses a threat.

The penultimate goal for this program is to serve as a critical component of the Nation’s pandemic response for influenza and any other emerging infectious diseases, collaboratively working with BARDA to develop multiple products using a single, flexible platform capability.

## Publications

- September 3, 2024: Special notice, due December 16, 2024 at 1:00 PM EST. Notice e6e00ff3a2ee4b69af18ae7b8d5d6f1c. https://sam.gov/workspace/contract/opp/e6e00ff3a2ee4b69af18ae7b8d5d6f1c/view

## Points of contact

- Rebecca Harmon, rebecca.harmon@ati.org

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/rrpvrpp2408mrnalongterm.